Treatment of Ocular Cancers with p53 Activators (SJ-06-0004)





Technology Name
(St. Jude Reference #)
Treatment of Ocular Cancers with p53 Activators
(SJ-06-0004)
Description Treatment of ocular cancers, such as retinoblastoma, using activators of the p53 pathway is provided. Compounds which inhibit the effect of MDM2 and MDMX on p53, such as nutlin-3, are identified as useful for activating p53 and treating ocular cancers.
Keywords MDMX, MDM2, p53, retinoblastoma, nutlin
Granted Patents or Published Applications US 8,470,785; 8,614,192
Related Scientific References Laurie, N.A. et al., “Targeting MDM2 and MDMX in retinoblastoma”, Curr. Cancer Drug Targets 7(7): 689-695 (2007); Marine, J.C. et al., “MDMX: from bench to bedside”, J. Cell Science 120(Pt3): 371-378 (2007); Laurie, N.A. et al., “Inactivation of the p53 pathway in retinoblastoma”, Nature 444(7115): 61-66 (2006).
Licensing Opportunities We are currently seeking licensing opportunities in all fields for the development of this technology.
   

Contact the Office of Technology Licensing (Phone: 901-595-2342, Fax: 901-595-3148) for more information.

Last update: April 2014